BeiGene

BeiGene is a Chinese life sciences biotechnology company that focuses on discovering and developing oncology drugs that address unmet medical needs in cancers prevalent in China and the Asia-Pacific region.

Founded in 2010, BeiGene specialise in novel drug discovery in the areas of both small molecules and biologicals, translational research with an emphasis on biomarker identification and validation in patients and bioinformatics based on human tumor genotyping and expression profiling.

With a broad portfolio, Beigene is expediting development of its diverse pipeline of novel therapeutics through internal capabilities and collaborations.

In January 2023, BeiGene's oral Bruton tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib), which recently gained US FDA approval for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). The drug gained approval after outperforming AbbVie’s Imbruvica (ibrutinib), which was the the standard of care in CLL for almost a decade.

Latest BeiGene News & Features